Please login to the form below
neurodegeneration
This page shows the latest neurodegeneration news and features for those working in and with pharma, biotech and healthcare.
Theranexus takes Alzheimer’s drug combo into clinic
While the ultimate aim of AD therapy is to develop treatments that affect the underlying cause of the neurodegeneration that leads to dementia, dozens of failed trials – particularly for anti-amyloid
Latest news
-
Morning brief: New biotech launched, Merck and Moderna expand collaboration and more
Preclinical data suggest this could lead to treatments for diseases including lysosomal storage disorders, liver and muscle diseases, inflammatory disorders and neurodegeneration.
-
Axovant joins ever-growing Alzheimer’s failure club
have no effect on the underlying neurodegeneration in the disease.
-
Celgene pays $300m upfront for immunology start-up Delinia
The Delinia acquisition comes in the wake of other bolt-on deals most recently its takeover earlier this month of another immunology specialist - Anokion - and its December purchase of oncology, neurodegeneration
-
Lilly streamlines and culls leadership roles
Shaw will lead the division's focus on immunology, neurodegeneration and pain, as well as a number of the firm's already established treatments. ... Ricks added: "With new medicines recently launched - and potential new medicines in development for cancer
-
Lundbeck trial failure dashes hopes in Alzheimer's once again
the underlying neurodegeneration in Alzheimer's.
More from news
Approximately 1 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
Dicerna/. Lilly. GalXC™ RNAi technology platform for targets in Cardiometabolic disease, neurodegeneration and pain.
-
Key considerations for disease- modifying Parkinson’s disease trials
dopamine due to neurodegeneration.
-
Holding on to hope for Alzheimer’s advances
abnormalities including seizures, neurodegeneration, cognitive deficits and hypomyelination… it is completely unclear whether BACE could be targeted in a manner to affect amyloid processing in a therapeutic manner, without serious
-
Pharma deals in September 2015
Gencia is also at the discovery phase in mitochondrial therapies in neurodegeneration, cardiovascular disease and other areas.
-
Pharma deals during February 2014
adolescence, and ultimately neurodegeneration due to the formation of fatty yellow nodules (xanthomas) in the brain.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Lilly strengthens team with in-house promotions
Importantly, this team will help us maintain focus as we work to bring forward new medicines in diabetes, cancer, immunology, neurodegeneration and pain.”.
-
Asceneuron appoints chief medical officer
He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011.
-
Nouscom appoints COO and board members
Prior to this, she was the global head of neurodegeneration at Novartis, and worked in the healthcare sector of McKinsey &Company in Chicago.
-
Polleo Pharma co-founders join Chronos Therapeutics
Dr Murray (pictured above) brings over 20 years of drug discovery and early development experience to the role, spread across a range of therapeutic areas including dermatology, inflammation, neurodegeneration, psychiatry.
-
Sanofi appoints Pfizer's Rita Balice-Gordon to lead neurobiology research
including neurodegeneration, neuroinflammation and central nervous system inherited diseases.
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Featured jobs
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Account Manager
-
Negotiable
-
Systematic Reviewer - Oxford
-
Negotiable
-
Associate Director
-
£75, 000-90, 000
-
Senior Account Manager
-
Competitive Salary Offered
- Account Manager- Healthcare Advertising
-
Negotiable
-
Associate Medical Director
-
Excellent PTO, bonus and 401k package
- Principal Health Economist - North-West
-
Negotiable
-
Account Director
-
Competitive Salary Offered
- Senior Account Executive with progression to Account Manager, Me...
-
Excellent package
-
Medical (Scientific) Director
-
£120, 000 benefits
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Business Director
-
Competitive Salary Offered
- Business Development Director – Health Education
-
excellent commission
-
Account Manager / Account Director
-
Competative
Subscribe to our email news alerts
- Industry frustrated by late warning on 'no deal' Brexit disruption
- UK’s genomics leadership attracts IQVIA investment, regardless of Brexit
- Lucid Group celebrate another magical year at their Winter Meeting
- Biogen picks up another drug from wide-ranging Ionis alliance
- As France protests, Sanofi takes axe to 670 jobs
- Leicester NHS Trust’s staff intranet is integral to HCPs’ working day
PMHub
Just::Health Communications
Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...
Latest intelligence
- Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
- What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
- What everyone forgets about good organisational change in pharma
- Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
- Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
- Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...
Quick links
Infographics
